From GlobeNewswire: 2025-05-13 21:00:00

Belite Bio, Inc. received positive feedback from the Data Safety Monitoring Board on their Phase 3 trial of Tinlarebant in adolescent Stargardt disease patients, allowing the trial to proceed without modification. Another Phase 3 trial for Tinlarebant in geographic atrophy patients is ongoing. The company also raised $15 million in a recent offering. Financial results for the first quarter of 2025 show $157.4 million in current assets. A webcast is scheduled for May 14, 2025, to discuss these updates. Belite Bio aims to deliver new treatment options for degenerative retinal diseases.

Source: Globe Newswire



Read more at GlobeNewswire: Belite Bio Reports First Quarter 2025 Financial Results and